Publications 2024

Caulier B, Joaquina S, Gelebart P, Dowling TH, Kaveh F, Thomas M, Tandaric L, Wernhoff P, Katyayini NU, Wogsland C, Gjerstad ME, Fløisand Y, Kvalheim G, Marr C, Kobold S, Enserink JM, Gjertsen BT, McCormack E, Inderberg EM, Wälchli S (2024)
CD37 is a safe chimeric antigen receptor target to treat acute myeloid leukemia
Cell Rep Med, 5 (6), 101572
DOI 10.1016/j.xcrm.2024.101572, PubMed 38754420

Chen YB, Mohty M, Zeiser R, Teshima T, Jamy O, Maertens J, Purtill D, Chen J, Cao H, Rossiter G, Jansson J, Fløisand Y (2024)
Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial
Nat Med, 30 (8), 2277-2287
DOI 10.1038/s41591-024-03016-4, PubMed 38844797

Grønvold BL, Ali MM, Myklebust TÅ, Lenartova A, Remberger M, Abrahamsen IW, Tjønnfjord GE, Myhre AE, Fløisand Y, Gedde-Dahl T (2024)
Allogeneic stem cell transplant recipients surviving at least 2 years without relapse: outcome and risk factors
EJHaem, 5 (1), 117-124
DOI 10.1002/jha2.842, PubMed 38406518

Kleftogiannnis D, Gavasso S, Tislevoll BS, van der Meer N, Motzfeldt IKF, Hellesøy M, Gullaksen SE, Griessinger E, Fagerholt O, Lenartova A, Fløisand Y, Schuringa JJ, Gjertsen BT, Jonassen I (2024)
Automated cell type annotation and exploration of single-cell signaling dynamics using mass cytometry
iScience, 27 (7), 110261
DOI 10.1016/j.isci.2024.110261, PubMed 39021803

Mehta P, Campbell V, Maddox J, Floisand Y, Kalakonda AJM, O'Nions J, Coats T, Nagumantry S, Hodgson K, Whitmill R, Amott I, Flynn G, Taussig D, Zhao R, Cunningham N, Roset M, Cuadras D, Medalla G, Kuter H, Park S, Legg A, Khan AB (2024)
CREST-UK: Real-world effectiveness, safety and outpatient delivery of CPX-351 for first-line treatment of newly diagnosed therapy-related AML and AML with myelodysplasia-related changes in the UK
Br J Haematol, 205 (4), 1326-1336
DOI 10.1111/bjh.19622, PubMed 38977430

van der Maas NG, Versluis J, Nasserinejad K, van Rosmalen J, Pabst T, Maertens J, Breems D, Manz M, Cloos J, Ossenkoppele GJ, Floisand Y, Gradowska P, Löwenberg B, Huls G, Postmus D, Pignatti F, Cornelissen JJ (2024)
Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial
Blood Cancer J, 14 (1), 56
DOI 10.1038/s41408-024-01037-3, PubMed 38538587

Publications 2023

Andersen AN, Brodersen AM, Ayuda-Durán P, Piechaczyk L, Tadele DS, Baken L, Fredriksen J, Stoksflod M, Lenartova A, Fløisand Y, Skånland SS, Enserink JM (2023)
Clinical forecasting of acute myeloid leukemia using ex vivo drug-sensitivity profiling
Cell Rep Methods, 3 (12), 100654
DOI 10.1016/j.crmeth.2023.100654, PubMed 38065095

Fløisand Y, Remberger M, Bigalke I, Josefsen D, Vålerhaugen H, Inderberg EM, Olaussen RW, Gjertsen BT, Goedkoop R, Geiger C, Prinz PU, Schnorfeil FM, Pinkernell K, Schendel DJ, Kvalheim G (2023)
WT1 and PRAME RNA-loaded dendritic cell vaccine as maintenance therapy in de novo AML after intensive induction chemotherapy
Leukemia, 37 (9), 1842-1849
DOI 10.1038/s41375-023-01980-3, PubMed 37507426

Tislevoll BS, Hellesøy M, Fagerholt OHE, Gullaksen SE, Srivastava A, Birkeland E, Kleftogiannis D, Ayuda-Durán P, Piechaczyk L, Tadele DS, Skavland J, Baliakas P, Hovland R, Andresen V, Seternes OM, Tvedt THA, Aghaeepour N, Gavasso S, Porkka K, Jonassen I, Fløisand Y, Enserink J, Blaser N, Gjertsen BT (2023)
Early response evaluation by single cell signaling profiling in acute myeloid leukemia
Nat Commun, 14 (1), 115
DOI 10.1038/s41467-022-35624-4, PubMed 36611026

Tislevoll BS, Hellesøy M, Fagerholt OHE, Gullaksen SE, Srivastava A, Birkeland E, Kleftogiannis D, Ayuda-Durán P, Piechaczyk L, Tadele DS, Skavland J, Baliakas P, Hovland R, Andresen V, Seternes OM, Tvedt THA, Aghaeepour N, Gavasso S, Porkka K, Jonassen I, Fløisand Y, Enserink J, Blaser N, Gjertsen BT (2023)
Author Correction: Early response evaluation by single cell signaling profiling in acute myeloid leukemia
Nat Commun, 14 (1), 1767
DOI 10.1038/s41467-023-37488-8, PubMed 36997540

Vo CD, Myhre AE, Abrahamsen IW, Remberger M, Mattsson J, Fløisand Y, Grønvold BCL, Tjønnfjord GE, Tvedt THA, Gedde-Dahl T (2023)
Allogeneic stem cell transplantation in adults 2015-21
Tidsskr Nor Laegeforen, 143 (4)
DOI 10.4045/tidsskr.22.0521, PubMed 36919291

Publications 2022

Garcia-Horton A, Cyriac SL, Gedde-Dahl T, Floisand Y, Remberger M, Mattsson J, Michelis FV (2022)
Patient age and donor HLA matching can stratify allogeneic hematopoietic cell transplantation patients into prognostic groups
Eur J Haematol, 109 (6), 672-679
DOI 10.1111/ejh.13850, PubMed 36028979

Griffin JM, Healy FM, Dahal LN, Floisand Y, Woolley JF (2022)
Worked to the bone: antibody-based conditioning as the future of transplant biology
J Hematol Oncol, 15 (1), 65
DOI 10.1186/s13045-022-01284-6, PubMed 35590415

Grob T, Sanders MA, Vonk CM, Kavelaars FG, Rijken M, Hanekamp DW, Gradowska PL, Cloos J, Fløisand Y, van Marwijk Kooy M, Manz MG, Ossenkoppele GJ, Tick LW, Havelange V, Löwenberg B, Jongen-Lavrencic M, Valk PJM (2022)
Prognostic Value of FLT3-Internal Tandem Duplication Residual Disease in Acute Myeloid Leukemia
J Clin Oncol, 41 (4), 756-765
DOI 10.1200/JCO.22.00715, PubMed 36315929

Lim YJ, Khan U, Karpha I, Ross A, Saif M, Remberger M, Kalakonda N, Pettitt AR, Floisand Y (2022)
COVID-19 outcomes in haematopoietic cell transplant recipients: A systematic review and meta-analysis
EJHaem, 3 (3), 862-872
DOI 10.1002/jha2.465, PubMed 35941880

Publications 2021

Ali MM, Grønvold B, Remberger M, Abrahamsen IW, Myhre AE, Tjønnfjord GE, Fløisand Y, Gedde-Dahl T (2021)
Addition of Anti-thymocyte Globulin in Allogeneic Stem Cell Transplantation With Peripheral Stem Cells From Matched Unrelated Donors Improves Graft-Versus-Host Disease and Relapse Free Survival
Clin Lymphoma Myeloma Leuk, 21 (9), 598-605
DOI 10.1016/j.clml.2021.05.003, PubMed 34158268

Berishvili E, Kaiser L, Cohen M, Berney T, Scholz H, Floisand Y, Mattsson J (2021)
Treatment of COVID-19 Pneumonia: the Case for Placenta-derived Cell Therapy
Stem Cell Rev Rep, 17 (1), 63-70
DOI 10.1007/s12015-020-10004-x, PubMed 32696426

Fløisand Y, Schroeder MA, Chevallier P, Selleslag D, Devine S, Renteria AS, Mohty M, Yakoub-Agha I, Chen C, Parfionovas A, Quadri S, Jansson J, Akbari M, Chen YB (2021)
A phase 2a randomized clinical trial of intravenous vedolizumab for the treatment of steroid-refractory intestinal acute graft-versus-host disease
Bone Marrow Transplant, 56 (10), 2477-2488
DOI 10.1038/s41409-021-01356-0, PubMed 34108672

Healy FM, Dahal LN, Jones JRE, Floisand Y, Woolley JF (2021)
Recent Progress in Interferon Therapy for Myeloid Malignancies
Front Oncol, 11, 769628
DOI 10.3389/fonc.2021.769628, PubMed 34778087

Jørgensen SF, Buechner J, Myhre AE, Galteland E, Spetalen S, Kulseth MA, Sorte HS, Holla ØL, Lundman E, Alme C, Heier I, Flægstad T, Fløisand Y, Benneche A, Fevang B, Aukrust P, Stray-Pedersen A, Gedde-Dahl T, Nordøy I (2021)
A Nationwide Study of GATA2 Deficiency in Norway-the Majority of Patients Have Undergone Allo-HSCT
J Clin Immunol, 42 (2), 404-420
DOI 10.1007/s10875-021-01189-y, PubMed 34893945

Löwenberg B, Pabst T, Maertens J, Gradowska P, Biemond BJ, Spertini O, Vellenga E, Griskevicius L, Tick LW, Jongen-Lavrencic M, van Marwijk Kooy M, Vekemans MC, van der Velden WJFM, Beverloo B, Michaux L, Graux C, Deeren D, de Weerdt O, van Esser JWJ, Bargetzi M, Klein SK, Gadisseur A, Westerweel PE, Veelken H, Gregor M et al. (2021)
Addition of lenalidomide to intensive treatment in younger and middle-aged adults with newly diagnosed AML: the HOVON-SAKK-132 trial
Blood Adv, 5 (4), 1110-1121
DOI 10.1182/bloodadvances.2020003855, PubMed 33616652

Quiles-Jiménez A, Gregersen I, Segers FM, Skarpengland T, Kroustallaki P, Yang K, Kong XY, Lauritzen KH, Olsen MB, Karlsen TR, Nyman TA, Sagen EL, Bjerkeli V, Suganthan R, Nygård S, Scheffler K, Prins J, Van der Veer E, Øgaard JD, Fløisand Y, Jørgensen HF, Holven KB, Biessen EA, Nilsen H, Dahl TB et al. (2021)
DNA glycosylase Neil3 regulates vascular smooth muscle cell biology during atherosclerosis development
Atherosclerosis, 324, 123-132
DOI 10.1016/j.atherosclerosis.2021.02.023, PubMed 33714552

Remberger M, Tjønnfjord GE, Abrahamsen IW, Ali M, Myhre AE, Gedde-Dahl T, Fløisand Y (2021)
Superior Graft-versus-Host Disease-Free Relapse-Free Survival in Matched Unrelated Donor Hematopoietic Stem Cell Transplantation with Anti-Thymocyte Globulin (ATG) Compared to Matched Related Donor without ATG
Transplant Cell Ther, 27 (7), 621.e1-621.e3
DOI 10.1016/j.jtct.2021.03.019, PubMed 33895156

Publications 2020

Bazarbachi A, Bug G, Baron F, Brissot E, Ciceri F, Dalle IA, Döhner H, Esteve J, Floisand Y, Giebel S, Gilleece M, Gorin NC, Jabbour E, Aljurf M, Kantarjian H, Kharfan-Dabaja M, Labopin M, Lanza F, Malard F, Peric Z, Prebet T, Ravandi F, Ruggeri A, Sanz J, Schmid C et al. (2020)
Clinical practice recommendation on hematopoietic stem cell transplantation for acute myeloid leukemia patients with FLT3-internal tandem duplication: a position statement from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
Haematologica, 105 (6), 1507-1516
DOI 10.3324/haematol.2019.243410, PubMed 32241850

Broch K, Popperud T, Gude E, Fløisand Y, Antal EA, Bosse G, Jonsrud C, Hegard T, Skaara S, Elsais A (2020)
A Middle-Aged Man Presenting With Progressive Heart Failure, Myopathy, and Monoclonal Gammopathy of Uncertain Significance
JACC Case Rep, 2 (5), 785-789
DOI 10.1016/j.jaccas.2020.02.024, PubMed 34317348

Derolf Å, Juliusson G, Benson L, Fløisand Y, Lazarevic V, Antunovic P, Möllgård L, Lehmann S, Uggla B, Wahlin A, Höglund M, Deneberg S (2020)
Decreasing early mortality in acute myeloid leukaemia in Sweden 1997-2014: improving performance status is a major contributing factor
Br J Haematol, 188 (1), 187-191
DOI 10.1111/bjh.16265, PubMed 31863470

Grønvold B, Ali MM, Remberger M, Mattsson J, Egeland T, Lundin KU, Myhre AE, Abrahamsen IW, Heldal D, Dybedal I, Tjønnfjord GE, Fløisand Y, Gedde-Dahl T (2020)
HLA-DPB1 mismatch reduce relapse and improve survival in T-cell replete unrelated donor allogeneic stem cell transplantation
Bone Marrow Transplant, 55 (8), 1658-1661
DOI 10.1038/s41409-020-0827-3, PubMed 32054997

Remberger M, Grønvold B, Ali M, Mattsson J, Egeland T, Lundin KU, Myhre A, Abrahamsen I, Heldal D, Dybedal I, Tjønnfjord GE, Gedde-Dahl T, Fløisand Y (2020)
The CD34⁺ Cell Dose Matters in Hematopoietic Stem Cell Transplantation with Peripheral Blood Stem Cells from Sibling Donors
Clin Hematol Int, 2 (2), 74-81
DOI 10.2991/chi.d.200221.001, PubMed 34595446

Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, Socié G, Platzbecker U, Beelen D, Milpied N, Cornelissen JJ, Ganser A, Huynh A, Griskevicius L, Giebel S, Aljurf M, Brissot E, Malard F, Esteve J, Peric Z, Baron F, Ruggeri A, Schmid C, Gilleece M, Gorin NC et al. (2020)
Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
Bone Marrow Transplant, 55 (6), 1114-1125
DOI 10.1038/s41409-020-0803-y, PubMed 31996792

Spyridonidis A, Labopin M, Savani BN, Niittyvuopio R, Blaise D, Craddock C, Socié G, Platzbecker U, Beelen D, Milpied N, Cornelissen JJ, Ganser A, Huynh A, Griskevicius L, Giebel S, Aljurf M, Brissot E, Malard F, Esteve J, Peric Z, Baron F, Ruggeri A, Schmid C, Gilleece M, Gorin NC et al. (2020)
Correction: Redefining and measuring transplant conditioning intensity in current era: a study in acute myeloid leukemia patients
Bone Marrow Transplant, 55 (6), 1213
DOI 10.1038/s41409-020-0835-3, PubMed 32144364

Tadele DS, Robertson J, Crispin R, Herrera MC, Chlubnová M, Piechaczyk L, Ayuda-Durán P, Singh SK, Gedde-Dahl T, Fløisand Y, Skavland J, Wesche J, Gjertsen BT, Enserink JM (2020)
A cell competition-based small molecule screen identifies a novel compound that induces dual c-Myc depletion and p53 activation
J Biol Chem, 296, 100179
DOI 10.1074/jbc.RA120.015285, PubMed 33303632

Publications 2019

Sioud M, Pettersen S, Ailte I, Fløisand Y (2019)
Targeted Killing of Monocytes/Macrophages and Myeloid Leukemia Cells with Pro-Apoptotic Peptides
Cancers (Basel), 11 (8)
DOI 10.3390/cancers11081088, PubMed 31370273

Saad A, Lamb L, Wang T, Hemmer MT, Spellman S, Couriel D, Alousi A, Pidala J, Abdel-Azim H, Agrawal V, Aljurf M, Beitinjaneh AM, Bhatt VR, Buchbinder D, Byrne M, Cahn JY, Cairo M, Castillo P, Chhabra S, Diaz MA, Farhan S, Floisand Y, Frangoul HA, Gadalla SM, Gajewski J et al. (2019)
Impact of T Cell Dose on Outcome of T Cell-Replete HLA-Matched Allogeneic Peripheral Blood Stem Cell Transplantation
Biol Blood Marrow Transplant, 25 (9), 1875-1883
DOI 10.1016/j.bbmt.2019.05.007, PubMed 31085303

Thomas AM, Gerogianni A, McAdam MB, Fløisand Y, Lau C, Espevik T, Nilsson PH, Mollnes TE, Barratt-Due A (2019)
Complement Component C5 and TLR Molecule CD14 Mediate Heme-Induced Thromboinflammation in Human Blood
J Immunol, 203 (6), 1571-1578
DOI 10.4049/jimmunol.1900047, PubMed 31413105

Zhang B, Ayuda-Durán P, Piechaczyk L, Fløisand Y, Safont MM, Karlsen IT, Fandalyuk Z, Tadele D, van Mierlo P, Rowe AD, Robertson JM, Gjertsen BT, McCormack E, Enserink JM (2019)
GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells
Haematologica, 104 (5), e229
DOI 10.3324/haematol.2019.220533, PubMed 31040234

Publications 2018

Danylesko I, Bukauskas A, Paulson M, Peceliunas V, Gedde-Dahl D Y T, Shimoni A, Shouval R, Griskevicius L, Floisand Y, Nagler A (2018)
Anti-α4β7 integrin monoclonal antibody (vedolizumab) for the treatment of steroid-resistant severe intestinal acute graft-versus-host disease
Bone Marrow Transplant, 54 (7), 987-993
DOI 10.1038/s41409-018-0364-5, PubMed 30356163

Diep PP, Melberg HO, Brinch L, Buechner J, Fløisand Y, Gedde-Dahl T, Loge JH, Tjønnfjord GE, Ruud E (2018)
Cost-utility of allogeneic hematopoietic stem cell transplantation in Norway
Bone Marrow Transplant, 53 (5), 657-660
DOI 10.1038/s41409-018-0091-y, PubMed 29358600

Fløisand Y, Lazarevic VL, Maertens J, Mattsson J, Shah NN, Zachée P, Taylor A, Akbari M, Quadri S, Parfionovas A, Chen YB (2018)
Safety and Effectiveness of Vedolizumab in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease: A Retrospective Record Review
Biol Blood Marrow Transplant, 25 (4), 720-727
DOI 10.1016/j.bbmt.2018.11.013, PubMed 30468919

Sioud M, Westby P, Vasovic V, Fløisand Y, Peng Q (2018)
Development of a new high-affinity human antibody with antitumor activity against solid and blood malignancies
FASEB J, 32 (9), 5063-5077
DOI 10.1096/fj.201701544R, PubMed 29913558

Zhang B, Durán PA, Piechaczyk L, Fløisand Y, Safont MMS, Karlsen IT, Fandalyuk Z, Tadele D, Mierlo PV, Rowe AD, Robertson JM, Gjertsen BT, McCormack E, Enserink JM, Bjørn Tore Gjertsen Group, Emmet McCormack Group (2018)
GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells
Haematologica, Online ahead of print (in press) (Retracted)
DOI 10.3324/haematol.2018.189399, PubMed 29748445

Publications 2017

Gustavsen A, Skattum L, Bergseth G, Lorentzen B, Floisand Y, Bosnes V, Mollnes TE, Barratt-Due A (2017)
Effect on mother and child of eculizumab given before caesarean section in a patient with severe antiphospholipid syndrome: A case report
Medicine (Baltimore), 96 (11), e6338
DOI 10.1097/MD.0000000000006338, PubMed 28296762

Ringdén O, Labopin M, Sadeghi B, Mailhol A, Beelen D, Fløisand Y, Ghavamzadeh A, Finke J, Ehninger G, Volin L, Socié G, Kröger N, Stuhler G, Ganser A, Schmid C, Giebel S, Mohty M, Nagler A (2017)
What is the outcome in patients with acute leukaemia who survive severe acute graft-versus-host disease?
J Intern Med, 283 (2), 166-177
DOI 10.1111/joim.12695, PubMed 29027756

Server A, Bargalló N, Fløisand Y, Sponheim J, Graus F, Hald JK (2017)
Imaging spectrum of central nervous system complications of hematopoietic stem cell and solid organ transplantation
Neuroradiology, 59 (2), 105-126
DOI 10.1007/s00234-017-1804-4, PubMed 28255902

Wang D, Fløisand Y, Myklebust CV, Bürgler S, Parente-Ribes A, Hofgaard PO, Bogen B, Taskén K, Tjønnfjord GE, Schjesvold F, Dalgaard J, Tveita A, Munthe LA (2017)
Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice
Leukemia, 31 (10), 2114-2121
DOI 10.1038/leu.2017.69, PubMed 28232741

Publications 2016

Barratt-Due A, Fløisand Y, Orrem HL, Kvam AK, Holme PA, Bergseth G, Tjønnfjord GE, Mollnes TE (2016)
Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome
Rheumatology (Oxford), 55 (7), 1337-9
DOI 10.1093/rheumatology/kew040, PubMed 27105662

Fløisand Y, Lundin KEA, Lazarevic V, Kristiansen JD, Osnes LTN, Tjønnfjord GE, Reims HM, Gedde-Dahl T (2016)
Targeting Integrin α4β7 in Steroid-Refractory Intestinal Graft-versus-Host Disease
Biol Blood Marrow Transplant, 23 (1), 172-175
DOI 10.1016/j.bbmt.2016.10.009, PubMed 27777142

Kontro M, Kumar A, Majumder MM, Eldfors S, Parsons A, Pemovska T, Saarela J, Yadav B, Malani D, Fløisand Y, Höglund M, Remes K, Gjertsen BT, Kallioniemi O, Wennerberg K, Heckman CA, Porkka K (2016)
HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia
Leukemia, 31 (2), 301-309
DOI 10.1038/leu.2016.222, PubMed 27499136

Torfoss D, Fladhagen T, Holte H, Brinch L, Schjesvold FH, Fløisand Y, Nyquist E, Dalgaard J, Meyer P, Lehmann AK, Hammerstrøm J, Skjelbakken T, Høiby EA, Sandvik L, Kvaløy S (2016)
Benzylpenicillin plus an aminoglycoside versus meropenem in neutropenic lymphoma and leukaemia patients with a suspected bacterial infection: a randomized, controlled trial
Clin Microbiol Infect, 23 (3), 179-187
DOI 10.1016/j.cmi.2016.10.019, PubMed 27793737

Publications 2015

Bremer S, Fløisand Y, Brinch L, Gedde-Dahl T, Bergan S (2015)
Glutathione Transferase Gene Variants Influence Busulfan Pharmacokinetics and Outcome After Myeloablative Conditioning
Ther Drug Monit, 37 (4), 493-500
DOI 10.1097/FTD.0000000000000180, PubMed 25565670

Høyvoll LR, Fløisand Y, Orrem HL, Gunnarsson R, Landrø L, Brevig T, Gaustad P, Nordøy I (2015)
Hemophagocytic lymphohistiocytosis in leprosy
Lepr Rev, 86 (4), 403-6
PubMed 26964439

Wennström L, Edslev PW, Abrahamsson J, Nørgaard JM, Fløisand Y, Forestier E, Gustafsson G, Heldrup J, Hovi L, Jahnukainen K, Jonsson OG, Lausen B, Palle J, Zeller B, Holmberg E, Juliusson G, Stockelberg D, Hasle H, Nordic Society of Paediatric Haematology and Oncology (NOPHO), Danish Acute Leukemia Group, Swedish Acute Myeloid Leukemia Group (2015)
Acute Myeloid Leukemia in Adolescents and Young Adults Treated in Pediatric and Adult Departments in the Nordic Countries
Pediatr Blood Cancer, 63 (1), 83-92
DOI 10.1002/pbc.25713, PubMed 26281822

Publications 2014

Husøy MA, Brinch L, Tjønnfjord GE, Gedde-Dahl T, Heldal D, Holme PA, Dybedal I, Kolstad A, Akkök ÇA, Rollag H, Gaustad P, Bergan S, Egeland T, Josefsen D, Kvalheim G, Fløisand Y (2014)
[Allogeneic stem-cell transplantation in adults 1985-2012: results and development]
Tidsskr Nor Laegeforen, 134 (16), 1569-75
DOI 10.4045/tidsskr.13.1415, PubMed 25178233

Kristiansen HA, Spetalen S, Fløisand Y, Heldal D (2014)
Eltrombopag in Good's Syndrome
Case Rep Hematol, 2014, 172139
DOI 10.1155/2014/172139, PubMed 25389501

Taraldsrud E, Fevang B, Aukrust P, Beiske KH, Fløisand Y, Frøland S, Rollag H, Olweus J (2014)
Common variable immunodeficiency revisited: normal generation of naturally occurring dendritic cells that respond to Toll-like receptors 7 and 9
Clin Exp Immunol, 175 (3), 439-48
DOI 10.1111/cei.12239, PubMed 24237110

Publications 2013

Fernandes AM, Herlofsen SR, Karlsen TA, Küchler AM, Fløisand Y, Brinchmann JE (2013)
Similar properties of chondrocytes from osteoarthritis joints and mesenchymal stem cells from healthy donors for tissue engineering of articular cartilage
PLoS One, 8 (5), e62994
DOI 10.1371/journal.pone.0062994, PubMed 23671648

Fløisand Y, Beiske K, Tjønnfjord GE, Heldal D, Bjerkehagen B, Revheim ME, Heim S, Bruland OS, Hall KS, Tierens A, Delabie J (2013)
Malignant phyllodes tumor and acute megakaryoblastic leukemia sharing a common clonal origin
Case Rep Hematol, 2013, 934781
DOI 10.1155/2013/934781, PubMed 24455338

Holm AM, Riise GC, Brinch L, Bjørtuft O, Iversen M, Simonsen S, Fløisand Y (2013)
Lung transplantation for bronchiolitis obliterans after allogeneic hematopoietic stem cell transplantation: unresolved questions
Transplantation, 96 (4), e21-2
DOI 10.1097/TP.0b013e31829df2c0, PubMed 23958883

Publications 2012

Cesaro S, Pillon M, Tridello G, Aljurf M, Martino R, Schroyens W, Nozzoli C, Barba P, Faraci M, Fagioli F, Cappelli B, Cordonnier C, Al-Mohareb F, Floisand Y, Greil J, Panizzolo IS, Santarone S (2012)
Relationship between clinical and BK virological response in patients with late hemorrhagic cystitis treated with cidofovir: a retrospective study from the European Group for Blood and Marrow Transplantation
Bone Marrow Transplant, 48 (6), 809-13
DOI 10.1038/bmt.2012.247, PubMed 23222380

Fløisand Y, Brinch L, Gedde-Dahl T, Tjønnfjord GE, Dybedal I, Holte H, Heldal D, Torfoss D, Aurlien E, Lauritzsen GF, Fosså A, Lehne G, Baggerød E, Kvalheim G, Egeland T, Bishop MR, Fowler DH, Kolstad A (2012)
Ultra-short course sirolimus contributes to effective GVHD prophylaxis after reduced-intensity allogeneic hematopoietic cell transplantation
Bone Marrow Transplant, 47 (12), 1552-7
DOI 10.1038/bmt.2012.63, PubMed 22522568

Fløisand Y, Tjønnfjord G, Beiske K (2012)
[Invasive fungal infection]
Tidsskr Nor Laegeforen, 132 (23-24), 2618
DOI 10.4045/tidsskr.12.0603, PubMed 23338093

Holm AM, Riise GC, Hansson L, Brinch L, Bjørtuft O, Iversen M, Simonsen S, Fløisand Y (2012)
Lung transplantation for bronchiolitis obliterans syndrome after allo-SCT
Bone Marrow Transplant, 48 (5), 703-7
DOI 10.1038/bmt.2012.197, PubMed 23064037

Publications 2011

Fløisand Y, Delabie J, Fosså A, Helseth E, Jacobsen EA, Rolke J, Tjønnfjord GE (2011)
Richter syndrome presenting as a solitary cerebellar tumor during first-line treatment for chronic lymphocytic leukemia
Leuk Lymphoma, 52 (10), 2007-9
DOI 10.3109/10428194.2011.580480, PubMed 21663503

Karlsen TA, Mirtaheri P, Shahdadfar A, Fløisand Y, Brinchmann JE (2011)
Effect of three-dimensional culture and incubator gas concentration on phenotype and differentiation capability of human mesenchymal stem cells
J Cell Biochem, 112 (2), 684-93
DOI 10.1002/jcb.22978, PubMed 21268090

Publications 2010

Fløisand Y (2010)
Studies on dendritic cell ontogeny, differentiation and function
In Series of dissertations submitted to the Faculty of Medicine, University of Oslo, Unipub, Oslo, no. 959, 1 b. (flere pag.)
BIBSYS 101339860, ISBN 978-82-8072-361-1

Fløisand Y, Sioud M (2010)
Recent advances in hematopoietic stem cell transplantation and perspectives of RNAi applications
Methods Mol Biol, 629, 507-23
DOI 10.1007/978-1-60761-657-3_30, PubMed 20387168

Sioud M, Mobergslien A, Boudabous A, Fløisand Y (2010)
Evidence for the involvement of galectin-3 in mesenchymal stem cell suppression of allogeneic T-cell proliferation
Scand J Immunol, 71 (4), 267-74
DOI 10.1111/j.1365-3083.2010.02378.x, PubMed 20384870

Sioud M, Mobergslien A, Boudabous A, Fløisand Y (2010)
Mesenchymal stem cell-mediated T cell suppression occurs through secreted galectins
Int J Oncol, 38 (2), 385-90
DOI 10.3892/ijo.2010.869, PubMed 21165555

Tangen JM, Fløisand Y, Haukås E, Naess IA, Skjelbakken T, Stapnes C, Tjønnfjord GE (2010)
[Survival in adults with acute lymphoblastic leukaemia]
Tidsskr Nor Laegeforen, 130 (17), 1710-3
DOI 10.4045/tidsskr.09.1293, PubMed 20835280

Publications 2009

Damås JK, Landrø L, Fevang B, Heggelund L, Tjønnfjord GE, Fløisand Y, Halvorsen B, Frøland SS, Aukrust P (2009)
Homeostatic chemokines CCL19 and CCL21 promote inflammation in human immunodeficiency virus-infected patients with ongoing viral replication
Clin Exp Immunol, 157 (3), 400-7
DOI 10.1111/j.1365-2249.2009.03976.x, PubMed 19664149

Sioud M, Fløisand Y (2009)
NOD2/CARD15 on bone marrow CD34+ hematopoietic cells mediates induction of cytokines and cell differentiation
J Leukoc Biol, 85 (6), 939-46
DOI 10.1189/jlb.1008650, PubMed 19244164

Taraldsrud E, Grøgaard HK, Solheim S, Lunde K, Fløisand Y, Arnesen H, Seljeflot I, Egeland T (2009)
Age and stress related phenotypical changes in bone marrow CD34+ cells
Scand J Clin Lab Invest, 69 (1), 79-84
DOI 10.1080/00365510802419447, PubMed 18836945

Publications 2008

Fløisand Y, Brinch L, Dybedal I, Gedde-Dahl T, Heldal D, Holme PA, Egeland T, Tjønnfjord GE (2008)
[Allogeneic stem cell transplantation in adults with acute lymphoblastic leukaemia]
Tidsskr Nor Laegeforen, 128 (22), 2563-6
PubMed 19023351

Tangen JM, Fløisand Y, Foss-Abrahamsen J, Haukås E, Naess IA, Skjelbakken T (2008)
[Survival in adults with acute myelogenous leukemia]
Tidsskr Nor Laegeforen, 128 (10), 1164-7
PubMed 18480864

Publications 2007

Dalgaard J, Fløisand Y, Stenersen M, Egeland T, Brinch L (2007)
[Non-myeloablative allogeneic stem cell transplantation]
Tidsskr Nor Laegeforen, 127 (6), 721-4
PubMed 17363982

Fløisand Y, Normann AP, Heim S, Lund-Johansen F, Tjønnfjord GE (2007)
High expression of CD7 on CD34+ cells is not linked to deletion of derivative chromosome 9 or lack of dendritic cells in chronic myeloid leukaemia
Scand J Clin Lab Invest, 68 (2), 93-8
DOI 10.1080/00365510701558477, PubMed 17852828

Furset G, Fløisand Y, Sioud M (2007)
Impaired expression of indoleamine 2, 3-dioxygenase in monocyte-derived dendritic cells in response to Toll-like receptor-7/8 ligands
Immunology, 123 (2), 263-71
DOI 10.1111/j.1365-2567.2007.02695.x, PubMed 17725606

Sioud M, Fløisand Y (2007)
TLR agonists induce the differentiation of human bone marrow CD34+ progenitors into CD11c+ CD80/86+ DC capable of inducing a Th1-type response
Eur J Immunol, 37 (10), 2834-46
DOI 10.1002/eji.200737112, PubMed 17853407

Publications 2006

Kvale EO, Fløisand Y, Lund-Johansen F, Rollag H, Farkas L, Ghanekar S, Brandtzaeg P, Jahnsen FL, Olweus J (2006)
Plasmacytoid DCs regulate recall responses by rapid induction of IL-10 in memory T cells
Blood, 109 (8), 3369-76
DOI 10.1182/blood-2006-06-031484, PubMed 17158235

Sioud M, Fløisand Y, Forfang L, Lund-Johansen F (2006)
Signaling through toll-like receptor 7/8 induces the differentiation of human bone marrow CD34+ progenitor cells along the myeloid lineage
J Mol Biol, 364 (5), 945-54
DOI 10.1016/j.jmb.2006.09.054, PubMed 17049554

Publications 2004

Fløisand Y, Brinch L, Gedde-Dahl T, Tjønnfjord GE (2004)
[Treatment of T-cell prolymphocytic leukemia with monoclonal anti- CD52 antibody (alemtuzumab]
Tidsskr Nor Laegeforen, 124 (6), 768-70
PubMed 15039804